1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

06 Jan 2026
Admin
News Article

Esco Aster Backs Shine-On’s First-in-Class HLA-G Exosome Program

Esco Aster is strengthening its position in advanced exosome manufacturing.

The Singapore-based CRDMO has announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program, marking a key milestone for both companies.

From Development to IND Clearance

The collaboration began in 2023, when Shine-On Biomedical engaged Esco Aster for cGMP services.

Scope of work included:

High-yield exosome development using Esco Aster’s proprietary cell line platform
Process, analytical, and formulation development
Exosome drug loading studies
GMP engineering runs
Stability studies to support regulatory filing

These efforts culminated in a successful US FDA IND clearance in Q1 2025.

What Makes SOB100 Noteworthy?

Shine-On’s lead asset, SOB100, is positioned as a potential first-in-class platform.

Key highlights:

HLA-G targeted exosome drug delivery carrier
IND cleared by the US FDA
Ongoing Phase I clinical study
Designed for versatility across small molecules, nucleic acids, and protein payloads

Preclinical data has shown promising biodistribution, supporting broader development potential.

Ongoing Technical Support

Beyond IND-enabling work, Esco Aster continues to support Shine-On through:

Exploratory exosome loading feasibility studies
Technical services tailored to future payload expansion

This keeps the program flexible as clinical data evolves.

Strengthening Singapore’s Exosome Manufacturing Ecosystem

This collaboration reinforces Esco Aster’s unique positioning as Singapore’s first fully homegrown, vertically integrated CRDMO for engineered cancer exosomes.

Core capabilities include:

End-to-end development from cell line creation to GMP manufacturing
Use of the patented 3D Tide Motion™ bioreactor
Lower COGS through multiple conditioned media harvests per run

Esco Aster is also active in:

Autologous cell therapy co-development in ASEAN
A T-cell reactivation platform targeting non-G12C KRAS-mutant NSCLC
Deployment of Mitosis™ Enterprise Solutions for future single-use cGMP workflows

A Broader Asia-Pacific Strategy

Esco Aster supports innovators across:

South Asia
ASEAN
Oceania

The region represents:

~USD 10.5 trillion GDP
~2.6 billion people

With strong clinical networks and R&D incentives, especially in Australia, the company enables IIT and FIM studies while keeping development costs in check.

Bottom Line

The Esco Aster–Shine-On partnership shows how specialized CRDMO expertise can accelerate next-generation drug delivery platforms.

With SOB100 now in the clinic, this collaboration places Singapore firmly on the global map for engineered exosome manufacturing and innovation.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!